Wegovy and the Liver: What You Should Know Before Starting

You have a liver condition and you're wondering whether Wegovy is even an option

It's a question our prescribers hear most weeks, and it's a fair one. A liver diagnosis can make people cautious about adding any new medicine, and weight-loss treatments have historically had a complicated relationship with liver health. Semaglutide sits in a different position. It is a GLP-1 receptor agonist that works by mimicking a gut hormone, slowing gastric emptying and reducing appetite; the liver is not the primary site of its action, and it is not metabolised the same way many other medicines are.

For people with obesity and a liver condition, weight loss itself is one of the most effective tools available for improving liver health, particularly in conditions like metabolic-associated steatohepatitis. The trial evidence behind Wegovy's weight-management licence, including the STEP 1 trial published in the New England Journal of Medicine, involved participants with a range of comorbidities. Liver disease did not automatically exclude trial participants, though specific criteria applied. Your own eligibility depends on the detail of your condition, which is exactly why a prescriber reviews every consultation individually. You can read more about how Wegovy works on our Wegovy overview page.

Severe hepatic impairment is a different matter. The SmPC for semaglutide advises caution in that setting, and the BNF entry for semaglutide reflects this. If your liver disease is advanced, your prescriber may need to discuss the risk-benefit picture with your hepatologist before making a decision. No one should be self-prescribing in this situation.

What the July 2026 MHRA approval for MASH actually covers

On 3 July 2026, the MHRA granted a conditional marketing authorisation for semaglutide (Wegovy) to treat metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis in adults. This was a significant regulatory moment: the MHRA's announcement made the UK one of the first countries to approve a medicine specifically for this form of fatty liver disease.

It is worth being precise about what this means, though. The MASH indication is a separate authorisation from the weight-management licence. It covers a defined patient group with confirmed moderate-to-advanced fibrosis, assessed through specific clinical criteria. It is not a general licence for Wegovy in anyone with a fatty liver, and it does not mean that people with any liver condition are automatically suitable candidates for semaglutide. At nume, prescriptions are issued for weight management under the weight-management licence; the MASH indication is managed by hepatology and specialist services.

What the approval does signal is that semaglutide has undergone rigorous safety and efficacy review in people with significant liver disease, which is reassuring context if you have a milder liver condition and are considering it for weight loss. If you want to understand what effect Wegovy has on the liver in practical terms, we cover that in detail separately, and the evidence around how Wegovy affects liver function continues to build, and the regulatory picture is moving quickly.

Who can prescribe Wegovy when liver disease is in the mix, and what to tell them

The NHS notes that semaglutide is licensed for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition. Liver disease can count as a relevant comorbidity, but the licensing threshold is not the only gate: your prescriber will consider the type and severity of your liver condition, any other medicines you take, and whether semaglutide is clinically appropriate for you specifically. You can find the broader NHS guidance on weight-management injections on the NHS England site.

If you have a liver diagnosis, be ready to share the detail when you complete your consultation: what the condition is, how it was diagnosed, whether it is monitored, and what other medicines you take. This gives the prescriber what they need. If you are asking yourself whether Wegovy affects the liver before you get to that stage, our dedicated page walks through the current evidence in plain language. Liver conditions can sometimes affect how medicines are processed, and in more complex cases your prescriber may want a note from your GP or specialist before proceeding.

Pregnancy, breastfeeding, and trying to conceive are separate contraindications: semaglutide is not recommended in any of these situations, regardless of liver status, and women of childbearing age should discuss contraception with their prescriber before starting. The Wegovy and pregnancy page covers that in detail. Under-18s are not licensed for this treatment.

If you would like to explore whether Wegovy for weight management could be suitable for your circumstances, the right first step is a clinical assessment. Our prescribers review every consultation the same working day. You can also read more on our weight-loss treatments page, or explore the evidence on how semaglutide affects the liver before you decide.